MedTrace Logo

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

NCT05870839 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2024-12-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in healthy adults.

Conditions

Interventions

BIOLOGICAL

VXCO-100

Sterile liquid for injection

Sponsors & Collaborators

  • Vaccine Company, Inc.

    lead INDUSTRY

Principal Investigators

  • Justin Ortiz, MD, MS · University of Maryland

  • Nadine Rouphael, MD · Emory University

  • Angela Branche, MD · University of Rochester

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-11
Primary Completion
2024-04-10
Completion
2024-04-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05870839 on ClinicalTrials.gov